A Prospective, Open-label Study to Assess the Safety, Tolerability and Efficacy of Anidulafungin in the Treatment of Invasive Candidiasis in Children 2 to <18 Years of Age.
Τίτλος | A Prospective, Open-label Study to Assess the Safety, Tolerability and Efficacy of Anidulafungin in the Treatment of Invasive Candidiasis in Children 2 to <18 Years of Age. |
Publication Type | Journal Article |
Year of Publication | 2019 |
Authors | Roilides, E., Carlesse F., Leister-Tebbe H., Conte U., Yan J. L., Liu P., Tawadrous M., Aram J. A., & Queiroz-Telles F. |
Corporate Authors | Anidulafungin A8851008 Pediatric Study Group |
Journal | Pediatr Infect Dis J |
Volume | 38 |
Issue | 3 |
Pagination | 275-279 |
Date Published | 2019 03 |
ISSN | 1532-0987 |
Λέξεις κλειδιά | Administration, Intravenous, Adolescent, Anidulafungin, Antifungal Agents, Candida, Candidiasis, Invasive, Child, Child, Preschool, Drug Administration Schedule, Female, Humans, Internationality, Male, Prospective Studies, Treatment Outcome |
Abstract | BACKGROUND: Treatment with an echinocandin is recommended as first-line therapy for patients with invasive candidiasis (ICC) including candidemia. Little is known about the efficacy and safety of anidulafungin in children with ICC. |
DOI | 10.1097/INF.0000000000002237 |
Alternate Journal | Pediatr Infect Dis J |
PubMed ID | 30418357 |